Axon Enterprise (NASDAQ:AXON – Free Report) had its price target upped by JPMorgan Chase & Co. from $285.00 to $330.00 in a research note issued to investors on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.
A number of other research analysts have also recently issued reports on AXON. Barclays lifted their price objective on Axon Enterprise from $247.00 to $296.00 and gave the company an overweight rating in a research note on Tuesday, January 2nd. TheStreet upgraded Axon Enterprise from a c rating to a b rating in a research note on Tuesday, November 7th. Raymond James lifted their price objective on Axon Enterprise from $223.00 to $233.00 and gave the company an outperform rating in a research note on Wednesday, November 8th. Needham & Company LLC lifted their price objective on Axon Enterprise from $240.00 to $315.00 and gave the company a buy rating in a research note on Wednesday. Finally, Robert W. Baird boosted their price target on Axon Enterprise from $260.00 to $300.00 and gave the stock an outperform rating in a research note on Thursday, February 22nd. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has an average rating of Moderate Buy and an average price target of $293.90.
Read Our Latest Stock Analysis on Axon Enterprise
Axon Enterprise Stock Up 2.2 %
Shares of NASDAQ:AXON opened at $314.25 on Wednesday. The stock has a fifty day simple moving average of $260.37 and a two-hundred day simple moving average of $231.22. The stock has a market capitalization of $23.66 billion, a price-to-earnings ratio of 136.63 and a beta of 0.93. Axon Enterprise has a 12-month low of $175.37 and a 12-month high of $318.90. The company has a current ratio of 3.00, a quick ratio of 2.78 and a debt-to-equity ratio of 0.42.
Insider Buying and Selling at Axon Enterprise
In other Axon Enterprise news, President Joshua Isner sold 1,400 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $229.60, for a total transaction of $321,440.00. Following the completion of the sale, the president now owns 353,135 shares of the company’s stock, valued at $81,079,796. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Axon Enterprise news, President Joshua Isner sold 1,400 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $229.60, for a total transaction of $321,440.00. Following the completion of the sale, the president now owns 353,135 shares of the company’s stock, valued at $81,079,796. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey C. Kunins sold 2,729 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $230.79, for a total value of $629,825.91. Following the sale, the insider now directly owns 233,291 shares of the company’s stock, valued at approximately $53,841,229.89. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,281 shares of company stock valued at $10,811,720. Company insiders own 6.10% of the company’s stock.
Hedge Funds Weigh In On Axon Enterprise
Large investors have recently made changes to their positions in the business. Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 184.3% in the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock valued at $138,535,000 after acquiring an additional 451,350 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Axon Enterprise by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 147,345 shares of the biotechnology company’s stock valued at $29,320,000 after acquiring an additional 495 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Axon Enterprise by 11.5% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 63,778 shares of the biotechnology company’s stock valued at $12,691,000 after acquiring an additional 6,585 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Axon Enterprise by 66.4% in the second quarter. Nuveen Asset Management LLC now owns 405,773 shares of the biotechnology company’s stock valued at $79,174,000 after acquiring an additional 161,868 shares in the last quarter. Finally, Jump Financial LLC lifted its position in shares of Axon Enterprise by 672.6% in the third quarter. Jump Financial LLC now owns 23,262 shares of the biotechnology company’s stock valued at $4,629,000 after acquiring an additional 20,251 shares in the last quarter. 76.52% of the stock is currently owned by hedge funds and other institutional investors.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.
